Over the past 12‑18 months the hiv integrase strand transfer inhibitors insti industry trends have accelerated through a mix of strategic alliances, pipeline expansions, and regulatory shifts. In March 2024, Gilead Sciences entered a co‑development partnership with ViiV Healthcare to evaluate a next‑generation INSTI candidate that leverages a novel bicyclic scaffold, aiming to reduce dosing frequency. The same quarter, ViiV completed the acquisition of a boutique biotech, Avidity Biosciences, securing its proprietary capsid‑targeting delivery platform for INSTI formulations. February 2024 saw the FDA’s approval of Biktarvy XR, an extended‑release tablet that maintains therapeutic levels for 48 hours, prompting competitors to fast‑track similar long‑acting products. Meanwhile, the European Medicines Agency introduced a streamlined pathway for accelerated assessment of INSTI combinations, shortening time‑to‑market by an average of four months. On the financing front, early‑stage startup InnoVir received a $120 million Series C round to scale its RNA‑guided INSTI discovery platform, positioning it for a 2025 Phase I launch. Collectively, these moves signal a shift toward longer‑acting, combination‑ready regimens and heightened collaboration across the hiv integrase strand transfer inhibitors insti market.
